Can Zoliflodacin Replace Ceftriaxone for Super Gonorrhea?

Published: August 2025 | Last updated: May 2026

For the better part of a decade, the standard cure for gonorrhea was a 500 mg ceftriaxone shot in the clinic, full stop. That was the last antibiotic class still reliably working against the bug, and public-health agencies kept warning that resistance to ceftriaxone was a question of when, not if. In December 2025, the FDA approved a different option: zoliflodacin, branded NUZOLVENCE, a single 3 g oral dose for uncomplicated urogenital gonorrhea (Innoviva Specialty Therapeutics, December 12, 2025). It is the first new chemical class approved for gonorrhea in roughly 30 years.

This article walks through what that actually means: what the new drug does, where it fits in clinical practice, where it does not (yet), and why testing still has to come first. If you are weighing whether to test at home, the answers below point to the situation you are actually in, not a brochure version of it.

What changed in December 2025

Zoliflodacin had been in late-stage development for years through a not-for-profit collaboration between Innoviva Specialty Therapeutics and the Global Antibiotic Research and Development Partnership (GARDP). The pivotal Phase 3 study was the largest clinical trial ever run for a new gonorrhea treatment: 930 patients across 16 trial sites in Belgium, the Netherlands, South Africa, Thailand, and the United States (FDA approval announcement). The endpoint was microbiological cure of urogenital infection, and zoliflodacin met the non-inferiority bar against the ceftriaxone-plus-azithromycin reference regimen.

The FDA label limits the indication to uncomplicated urogenital gonorrhea in adults and adolescents aged 12 and older who weigh at least 35 kg. Pharyngeal (throat) infections and rectal infections were not part of the approved indication. That distinction sounds technical, but it matters in the real world, because gonorrhea regularly establishes itself at the throat and rectum without symptoms, and those sites are often the engine of community spread. For now, those infections still need the ceftriaxone shot.

One more piece of context: zoliflodacin is the first new chemical class approved for gonorrhea since the early 1990s. Ceftriaxone is a cephalosporin, a beta-lactam that disrupts the bacterial cell wall. Zoliflodacin belongs to a brand new class called spiropyrimidinetriones, which work on a different bacterial target entirely (a topoisomerase enzyme involved in DNA replication). That mechanistic difference is the whole reason public-health agencies have been hopeful: resistance to one class does not automatically mean resistance to the other.

How ceftriaxone and zoliflodacin work, side by side

Antibiotics kill bacteria by attacking specific machinery the bug needs to live or replicate. Two drugs hitting two different targets are unlikely to lose effectiveness at the same time, which is why a second mechanism in clinical use is a strategic win, not just a convenience.

Ceftriaxone is a third-generation cephalosporin given by intramuscular injection. The CDC has recommended a single 500 mg dose since 2020 (CDC Drug-Resistant Gonorrhea guidance). It binds to penicillin-binding proteins on the bacterial cell wall, blocks wall synthesis, and the cell ruptures under its own internal pressure. It works against most strains worldwide. Treatment failures are still rare in the United States, but they have been documented in several countries with active surveillance (WHO fact sheet).

Zoliflodacin (NUZOLVENCE) is taken as a single 3 g oral suspension. It inhibits a bacterial enzyme called type II topoisomerase, which Neisseria gonorrhoeae needs to unwind and re-coil its DNA during replication. Block the enzyme, the DNA stays knotted, and the bacterium cannot copy itself. Because the cell-wall machinery and the DNA-unwinding machinery are completely separate targets, strains that have developed ways to defeat cephalosporins are not protected from zoliflodacin by default. The Phase 3 trial intentionally included sites in high-prevalence regions to test the drug against contemporary strains, and it held up.

The Phase 3 trial: what the data actually showed

The Phase 3 study sponsored by GARDP enrolled 930 adults and adolescents with uncomplicated urogenital gonorrhea. Participants were randomly assigned either a single 3 g oral dose of zoliflodacin, or the dual reference therapy of 500 mg intramuscular ceftriaxone combined with 1 g oral azithromycin (study summary). The primary endpoint was microbiological cure at the urogenital site, measured by culture-based test of cure roughly a week after dosing.

Zoliflodacin met the predefined non-inferiority margin, meaning it did not perform meaningfully worse than the dual reference regimen. It cleared the urogenital infection in most patients who received it, and the effect held in subgroups that included strains with reduced susceptibility to historic frontline antibiotics. The trial was not designed to show zoliflodacin is better than ceftriaxone, only that it is comparable enough to be a credible alternative. That nuance matters: do not read non-inferiority as superiority.

Treatment-emergent side effects in the zoliflodacin arm skewed mild and self-limiting. The most commonly reported events were headache, transient decreases in certain white blood cell counts (neutropenia and leukopenia), and gastrointestinal complaints. No serious adverse events were attributed to the drug in the published trial summary. Long-term safety surveillance will continue as real-world use scales up, which is standard for any newly approved antibiotic.

Where each drug fits: indication boundaries matter

This part is easy to gloss over, and it is the part that determines what your clinician actually prescribes. Zoliflodacin is approved for uncomplicated urogenital gonorrhea, meaning infection of the urethra in men or the cervix in women, in patients aged 12 years and older who weigh at least 35 kg. The label does not yet cover pharyngeal infection (in the throat), rectal infection, disseminated gonococcal disease, gonococcal arthritis, neonatal infections, or pelvic inflammatory disease.

This is not a minor caveat. Pharyngeal gonorrhea is common, often symptomless, and a known reservoir for resistant strains because it sits next to commensal Neisseria species that swap genetic material with N. gonorrhoeae. Rectal gonorrhea is also frequently asymptomatic. Both routes drive ongoing transmission, and both currently still need ceftriaxone. Until the indication is expanded (and that requires further trials), zoliflodacin alone is not a substitute for the ceftriaxone shot when a clinician suspects extragenital infection.

Untreated gonorrhea carries real stakes beyond discomfort. Repeated or prolonged infection is a leading cause of pelvic inflammatory disease, which can scar the fallopian tubes and reduce fertility; in men, it can cause epididymitis with similar downstream risk. Active mucosal gonorrhea also raises HIV acquisition risk, because the local inflammation disrupts the mucosal barrier that normally limits HIV entry (CDC About Gonorrhea). Those downstream harms are the reason early detection and a completed course of antibiotics matter, not just for the current infection but for the years of fertility and exposure risk that follow.

For our home-testing readers, this matters in a specific way. Disclosure: stdrapidtestkits.com sells the rapid gonorrhea swab kit described in this article. Our at-home rapid gonorrhea kit uses a self-collected genital swab (vaginal or penile) and detects urogenital infection. If your exposure included oral or anal sex, a clinic visit for throat or rectal swab testing is still the right tool. We do not sell a pharyngeal or rectal swab kit; a positive at-home urogenital result does not rule out a separate throat or rectal infection.

Why super gonorrhea made this approval urgent

The phrase super gonorrhea is shorthand for strains of N. gonorrhoeae that resist multiple antibiotic classes, including the last reliable workhorse. The bug has burned through sulfonamides, penicillins, tetracyclines, macrolides, and fluoroquinolones in succession over the past 80 years. By 2020, cephalosporins were the only remaining first-line option in CDC and WHO guidance (CDC Drug-Resistant Gonorrhea).

Globally, gonorrhea is enormous. The WHO estimates 82 million new cases occurred in 2020 alone, with the highest incidence in the African and Western Pacific regions (WHO multi-drug-resistant gonorrhoea). The volume of infection is what creates evolutionary pressure: every untreated or partially treated case is a chance for the bacterium to acquire a resistance mutation and pass it on. Verified clinical treatment failures to ceftriaxone have already been reported in Australia, France, Japan, Slovenia, Sweden, and the United Kingdom (WHO multi-drug-resistant gonorrhoea), even though the United States has not yet confirmed one in routine surveillance.

Adding a structurally unrelated antibiotic to clinical practice does two things at once. First, it gives clinicians an option when a resistant strain emerges. Second, it slows down resistance to the older drug, because the new drug can carry some of the treatment load. Public-health agencies tend to favor holding zoliflodacin in reserve for situations where it is clearly needed, rather than blanket-replacing ceftriaxone overnight. Stewardship and resistance run in opposite directions: rotate antibiotics too aggressively and resistance simply chases the new one too.

Gonorrhea has developed resistance to nearly all the antibiotics used for its treatment. We are currently down to one last recommended and effective class of antibiotics, cephalosporins, to treat this common infection.

Side effects and tolerability: what to expect

Both drugs have well-characterized side effect profiles, and for most people they are mild and short-lived.

Ceftriaxone is a deep intramuscular injection, typically into the gluteus muscle. Many patients describe the injection itself as briefly painful, followed by local soreness for up to a day or two. Beyond the injection site, side effects are uncommon at the single 500 mg dose: occasional diarrhea, mild headache, or fatigue. Allergic reactions are the main safety concern; patients with a documented severe penicillin or cephalosporin allergy need an alternative regimen, which a clinician will select based on the individual case.

Zoliflodacin is taken by mouth as a single 3 g oral suspension, so there is no injection-site discomfort to manage. In the Phase 3 trial summary, the most common treatment-emergent events were headache (reported by roughly one in ten participants), transient reductions in certain white blood cell counts, and gastrointestinal symptoms such as loose stools or nausea. None of these were severe enough in the trial to be flagged as serious adverse events. Because the drug is new in clinical use, long-term safety data will continue to accumulate; clinicians and the FDA will track real-world adverse event reports as prescribing volume scales up.

For patients, the most practical difference is logistical. A single oral dose given in the same visit as the diagnosis can simplify the cascade from positive test to completed treatment, particularly for people who would otherwise need a separate appointment for an injection. That convenience matters for sticking with treatment, and treatment adherence is one of the levers that bends the resistance curve downward.

Gonorrhea At-Home Rapid Test

Gonorrhea At-Home Rapid Self-Test Kit

$59.00

Self-collected swab, lateral-flow rapid result in about 15 minutes. Useful when symptoms or recent exposure point at urogenital gonorrhea. A clinic visit is still the right path for pharyngeal or rectal testing, which our kit does not cover.

Test for Gonorrhea

Will zoliflodacin replace ceftriaxone everywhere?

Probably not, and probably not soon. The clinical and public-health communities have several reasons to keep both in active use. Ceftriaxone still works in the overwhelming majority of cases, and its label covers more anatomic sites than zoliflodacin does. Trial data on zoliflodacin for pharyngeal and rectal infections will need to mature before guideline writers can expand its role. Cost, supply, and global access also matter: ceftriaxone is generic, cheap, and widely distributed; a newly approved branded antibiotic takes time to reach every clinic that needs it.

The likely near-term pattern is dual availability. Ceftriaxone remains the workhorse for most cases, including throat and rectal infections. Zoliflodacin becomes the option when a ceftriaxone-resistant strain is identified, when a patient cannot tolerate the injection, when delivery logistics complicate the shot (rural clinics, mobile health programs), or when expanded indications eventually open up. Updated CDC treatment recommendations will follow the usual process: a careful review of evidence followed by formal guidance, rather than a same-day switch.

Testing first: the part that does not change

A new antibiotic is downstream of the same upstream question every reader has to answer: am I infected, and if so, where? Gonorrhea is often silent. Per CDC patient guidance, most women with gonococcal infection have no symptoms at all, and asymptomatic infection at the throat and rectum is common across genders. Silent infections are the ones that quietly drive transmission and give the bug more chances to develop resistance.

Testing windows depend on the technology. Lab-based nucleic acid amplification tests (NAATs) generally detect gonorrhea about one to two weeks after exposure, in line with standard CDC STI screening practice. Home-use rapid lateral-flow swab tests follow similar timing for symptomatic urogenital infection. Testing too soon after a known exposure can produce a false negative, which is why a single negative result close to exposure is not the same as an all-clear; a repeat test, or a clinic NAAT, may still be appropriate if exposure risk was high.

Chlamydia, Gonorrhea, and Syphilis 3-in-1 Home Test

3-in-1 Chlamydia, Gonorrhea & Syphilis Rapid Test Kit

$177.00

Many gonorrhea infections occur alongside chlamydia, and untreated syphilis travels in the same risk patterns. This combo kit screens all three from a single self-collection session: swab plus fingerstick blood test, results at home in about 15 minutes.

Screen for Three at Once

Prevention still does the heavy lifting

No antibiotic, however clever its mechanism, gets ahead of resistance if transmission keeps accelerating. Three things remain the strongest tools against gonorrhea, and they were the right tools before zoliflodacin and they are still the right tools now. Prevention is unglamorous, and that is precisely why it works. The drugs are a backstop for when prevention fails, not the primary plan.

1. U.S. Centers for Disease Control and Prevention. Drug-Resistant Gonorrhea: current status of cephalosporin susceptibility, the single 500 mg ceftriaxone recommendation, and ongoing resistance surveillance in the United States.
2. World Health Organization. Multi-drug-resistant gonorrhoea fact sheet: 82 million new global cases in 2020, documented ceftriaxone treatment failures in Australia, France, Japan, Slovenia, Sweden, and the United Kingdom, and the global resistance trend.
3. Innoviva Specialty Therapeutics, press release dated December 12, 2025. FDA approval of NUZOLVENCE (zoliflodacin) as a single-dose oral antibiotic for uncomplicated urogenital gonorrhea in patients aged 12 and older, weighing 35 kg or more; Phase 3 trial of 930 patients across 16 sites in Belgium, the Netherlands, South Africa, Thailand, and the United States; non-inferiority to ceftriaxone-plus-azithromycin.
4. U.S. Centers for Disease Control and Prevention. About Gonorrhea: transmission via vaginal, anal, and oral sex; asymptomatic infection at urogenital and extragenital sites; increased HIV acquisition risk in active mucosal infection.
5. Pharmacy Times. Editorial coverage of the FDA approval of zoliflodacin, summary of mechanism of action (topoisomerase inhibitor in the spiropyrimidinetrione class) and broader clinical context for the new oral regimen.
6. Global Antibiotic Research and Development Partnership (GARDP). Background on the not-for-profit Phase 3 trial sponsorship and the public-private collaboration that developed zoliflodacin for global access.

Maya Chen

Maya writes plain-English explainers on STI screening, prevention, and at-home testing. Background in epidemiology research at a state public-health department; articles synthesize CDC and peer-reviewed guidance, not personal clinical advice.